Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : Announces Upcoming Investor Conference Presentations

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 05:47am EST

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows.

Credit Suisse 28th Annual Healthcare Conference at 10:00 a.m. EST (8:00 a.m. MST) on Tuesday, November 12, 2019

Jefferies 2019 London Healthcare Conference at 9:00 a.m. EST (2:00 p.m. GMT) on Wednesday, November 20, 2019

The sessions may be accessed from the 'Investors & Media' page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. Replays of the webcasts will be archived on the Company's website.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite technologies, such as VelocImmune which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

Contact:

Tel: 914.847.7786

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
11/12REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
11/06REGENERON PHARMACEUTICALS : to Report Results from CD20xCD3 and BCMAxCD3 Bispeci..
PU
11/06REGENERON PHARMACEUTICALS : Provides Updates on Phase 3 Libtayo Development Prog..
AQ
11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
DJ
11/06REGENERON PHARMACEUTICALS : and Vyriad Announce Strategic Agreement for Discover..
PR
11/05Regeneron Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Si..
DJ
11/05REGENERON PHARMACEUTICALS : Board Approves $1 Billion Buyback
DJ
11/05REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
11/05REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
11/05Regeneron Pharmaceuticals Reports Higher 3Q Profit
DJ
More news
Financials (USD)
Sales 2019 7 782 M
EBIT 2019 2 283 M
Net income 2019 2 002 M
Finance 2019 5 371 M
Yield 2019 -
P/E ratio 2019 19,7x
P/E ratio 2020 15,7x
EV / Sales2019 4,15x
EV / Sales2020 3,69x
Capitalization 37 702 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 383,70  $
Last Close Price 344,87  $
Spread / Highest target 47,9%
Spread / Average Target 11,3%
Spread / Lowest Target -6,05%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-7.67%37 702
GILEAD SCIENCES4.03%82 323
VERTEX PHARMACEUTICALS26.61%53 950
WUXI APPTEC CO., LTD.81.65%22 459
GENMAB39.63%14 493
BEIGENE, LTD.41.34%12 019